Imperial College London

Dr Philippa C. May

Faculty of MedicineDepartment of Immunology and Inflammation

Visiting Researcher
 
 
 
//

Contact

 

philippa.may

 
 
//

Location

 

4N5Commonwealth BuildingHammersmith Campus

//

Summary

 

Summary

Philippa is a visiting researcher at Imperial College. She completed a PhD in leukaemia genomics in 2018, and recently finished her first post doc, funded by a Kay Kendall Leukaemia Fund project grant, in 2021.

Philippa's interest is in chromatin modification and non-coding regulatory elements in myeloid leukaemia. She uses various NGS-based methods, such as ChIP-seq, ATAC-seq and chromosome conformation capture-seq (4C). She was given an Early Career Development grant by Leukaemia UK in 2019.

Philippa is also an HCPC registered Clinical Scientist in Genetics and leads the Developmental Disorders at Guy's Hospital, using comparative genomic hybridisation to detect copy number imbalance in children with developmental delay.  She was previously the Head of Education and Development for Healthcare Science at the Royal Free London NHS Foundation Trust. 

Selected Publications

Journal Articles

Silvestri G, Trotta R, Stramucci L, et al., 2020, Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions., Blood Cancer Discov, Vol:1, Pages:48-67

Innes A, Wooley P, Szydlo R, et al., 2019, Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality., Leukemia, Vol:34, ISSN:1476-5551, Pages:667-670

Boulianne B, Robinson ME, May PC, et al., 2017, Lineage-specific genes are prominent DNA damage hotspots during leukemic transformation of B-cell precursors, Cell Reports, Vol:18, ISSN:2211-1247, Pages:1687-1698

Neviani P, Harb JG, Oaks JJ, et al., 2013, PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells, Journal of Clinical Investigation, Vol:123, ISSN:0021-9738, Pages:4144-4157

Neelakantan P, Gerrard G, Lucas C, et al., 2013, Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies, Blood, Vol:121, ISSN:0006-4971, Pages:2739-2742

Daghistani M, Marin D, Khorashad JS, et al., 2010, EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors, Blood, Vol:116, ISSN:0006-4971, Pages:6014-6017

Chapters

May PC, Khorashad JS, Alikian M, et al., 2016, The genetics of chronic myelogenous leukaemia, The Genetic Basis of Haematological Cancers, Editor(s): Reid, Tosi, John Wiley & Sons, ISBN:9781118528051

More Publications